Help on accessing alternative formats, such as Portable Document Format (PDF), Microsoft Word and PowerPoint (PPT) files, can be obtained in the alternate format help section.
Drugs are authorized for sale in Canada once they have successfully gone through the drug review process. This process is the means by which a drug application is reviewed by scientists in the Therapeutic Products Directorate (TPD) of Health Canada, and on occasion, outside experts, to assess the safety, efficacy and quality of a drug.
Throughout the process, the safety and well-being of Canadians is the paramount concern.
Health Canada's TPD is the national authority that regulates, evaluates and monitors the safety, efficacy, and quality of therapeutic and diagnostic products available to Canadians. These products include drugs, medical devices, disinfectants and sanitizers with disinfectant claims.
Drugs include both prescription and nonprescription pharmaceuticals; biologically-derived products such as vaccines, serums, and blood derived products; tissues and organs; disinfectants; and radiopharmaceuticals. According to the Food and Drugs Act, "a drug includes any substance or mixture of substances manufactured, sold or represented for use in:
Natural health products, such as vitamin and mineral supplements and herbal products, for which therapeutic claims are made are also regulated as drugs.
Research for new drugs begins with scientists developing various chemical or biological substances. Once a substance has been isolated and purified, it is administered to tissue cultures or to a variety of small animals to see whether or not there are significant changes. These changes may be biochemical, physiological or behavioural in nature.
If promising results are obtained from these initial studies, a variety of animal and laboratory tests are conducted to study other effects of the substance (e.g. how it effects the immune system or reproductive system) and to determine what dosage of the substance should be given to achieve a particular effect.
If these preclinical tests indicate that a substance produces the desired result and is not toxic, the sponsor (i.e., the person or company who takes responsibility for the application) will apply to the TPD for authorization to conduct a clinical trial.
The intent of a clinical trial is to research and gather information on a drug's dose, effectiveness and safety in humans. Trials are undertaken with informed and consenting human subjects according to good clinical practices. This provides a controlled environment where the procedures for drug administration and the evaluation of the results are closely monitored.
Prior to the commencement of a clinical trial in Canada, the TPD reviews the information submitted in the clinical trial application. This application requests permission to distribute the drug to responsible clinical investigators that are named in the application. Some of the information contained in a clinical trial application includes the results from preclinical tests, production methods, dosage form and information regarding the investigators who will be conducting the study.
If clinical trial studies prove that the drug has potential therapeutic value that outweighs the risks associated with its use (e.g. adverse effects, toxicity), the sponsor may choose to file a New Drug Submission with the TPD.
If there is insufficient evidence to support the safety, efficacy or quality claims, the TPD will not grant a marketing authorization for the drug. All drugs granted marketing authorization in Canada are reviewed to ensure that they meet the requirements of the Food and Drugs Act.
If the TPD decides not to grant a marketing authorization, the sponsor has the opportunity to supply additional information, to re-submit its submission at a later date with additional supporting data, or to appeal the TPD's decision.
The TPD has set internationally competitive performance targets for its conduct of reviews. The length of time for review depends on the product being submitted and the size and quality of the submission, and is influenced by TPD's workload and human resources. Currently, the process for the review of a drug takes an average of 18 months from the time that a sponsor submits a New Drug Submission until the TPD makes a marketing decision.
The TPD has been and continues to be committed to ensuring the drug review process is as efficient as possible. To do this, the TPD has implemented and is pursuing several initiatives to streamline the process including:
The TPD has a Priority Review Process in place which allows for a faster review to make available promising drug products for life-threatening or severely debilitating conditions, such as cancer, AIDS, or Parkinson's Disease, for which there are few effective therapies already on the market.
The Special Access Program, administered by the TPD, allows physicians to gain access to drugs which are not currently available in Canada. Following approval by the Special Access Programme, a physician may prescribe such a drug to specified patients, if it is the physician's belief that conventional therapies have failed or are inappropriate. The drug is only released after the TPD has determined that the need is legitimate and that a qualified physician is involved.
Once a new drug is on the market, regulatory controls continue. The distributor of the drug must report any new information received concerning serious side effects including failure of the drug to produce the desired effect. The distributor must also notify the TPD about any studies that have provided new safety information.
The TPD monitors adverse events, investigates complaints and problem reports, maintains post-approval surveillance, and manages recalls, should the necessity arise. In addition, the TPD licenses most drug production sites and conducts regular inspections as a condition for licensing. However, certain products such as natural health and homeopathic remedies, some veterinary drugs and vitamin and mineral supplements are not subject to these requirements.
Therapeutic Products Directorate
Holland Cross, Tower B
1600 Scott Street, 6th Floor
Address Locator 3106B
Ottawa, Ontario K1A 1B6
or visit our website: